Fig. 1
From: EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
EZH2 is high expressed in non–small-cell lung cancer (NSCLC) and is associated with poor prognosis in patients with lung adenocarcinoma. a Relative expression of EZH2 in NSCLC tissues compared with in paracancerous lung tissues in The Cancer Genome Atlas dataset. b EZH2 TPM in NSCLC and paracancerous lung tissues in TCGA dataset. c EZH2 expression levels in NSCLC tissues (n = 40) compared with those in paracancerous lung tissues (n = 40) by qPCR analysis; data were normalized against GAPDH expression level. d EZH2 protein levels in different NSCLC lines and the normal alveolar epithelial cell line BEAS-2B. e-f Overall survival curves of patients with LUAD and LUSC from the TCGA cohort. g–h Overall survival curves of patients with LUAD and LUSC from the TJMUGH cohort